Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | F10 | P00742 | 10/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6196515 | 0.99 | ATM (0.56) | ATMF10MEN1KMT2APOLB | |
| SCHEMBL6198612 | 0.88 | ATM (0.59) | ATMF10SMN1; SMN2F2LMNA | |
| Hydrochloric Acid SCHEMBL6196981 | 0.88 | ATM (0.58) | ATMF10SMN1; SMN2F2LMNA | |
| Hydrochloric Acid SCHEMBL6198549 | 0.87 | ATM (0.60) | ATMF10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5193868 | 0.85 | ATM (0.71) | ATMF10SMN1; SMN2F2LMNA | |
| Hydrochloric Acid SCHEMBL6195419 | 0.84 | ATM (0.69) | ATMF10SMN1; SMN2F2LMNA | |
| SCHEMBL6734223 | 0.81 | ATM (0.64) | ATMF10SMN1; SMN2F2LMNA | |
| SCHEMBL5734823 | 0.80 | ATM (0.60) | ATMF10SMN1; SMN2F2LMNA | |
| Hydrochloric Acid SCHEMBL6736713 | 0.80 | ATM (0.57) | ATMF10SMN1; SMN2F2LMNA | |
| SCHEMBL6305660 | 0.80 | ATM (0.68) | ATMF10MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1031563-B1 | SULFONYL DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20030232808-A1 | Sulfonyl derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-12-18 | — | — | US | disclosed |
| US-6525042-B1 | Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | ATM 2080/4885F10 19/4885MEN1 2216/4885 |
| US-20030232808-A1 | Sulfonyl derivatives | SULT1E1, SULT2A1, SULT1A1 | ATM 4186/4885F10 76/4885MEN1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.